SAN FRANCISCO (AP) — Bristol-Myers Squibb Co.'s CEO says its transformation into a biopharmaceutical company has already brought five new product launches and soon could bring two more, for a new blood thinner and a diabetes drug that could be big sellers.
Lamberto Andreotti says the company's revamped pipeline also has added to revenue, and increased productivity has boosted profit.
Meanwhile, Andreotti says the New York company is aiming to replace the current tough-to-endure mix of shots and pills for hepatitis C with a pill-only regimen that cures more patients and is easier to tolerate. That's behind Saturday's news that Bristol plans to buy hepatitis C drug developer Inhibitex Inc. for $2.5 billion.
Andreotti was speaking at the J.P. Morgan Global Healthcare Conference.